Best Growth Stocks this April 2026

With a modest dividend yield of 0.97% and a one-year return of -7.87%, the stock has faced recent challenges, yet it has delivered a strong 52.96% return over the last five years. Analysts remain cautiously optimistic, with a median 12-month price target of $600, reflecting potential upside despite mixed ratings, including a recent downgrade from Stifel to Hold. Investors should weigh the long-term growth prospects against short-term performance when considering an entry point.

The all-time high closing price for Microsoft stock was $539.83 on October 28, 2025.

With a robust 1-year return of 573.20% and a 5-year return of 471.36%, this investment demonstrates exceptional growth potential. While the dividend yield is relatively low at 0.14%, analysts are optimistic, providing a median 12-month price target of $306.00, supported by ratings of "Outperform" and "Buy" from major firms. Investors should consider the recent price drop of 7.70% as a potential entry point, given the strong upward trajectory and analyst confidence.

WDC is currently trading near its 52-week high but has dropped $22.79, or 7.70%, since the last market close.

Analysts' recommendations for Marathon Oil include 15% Strong Buy, 46% Buy, 38% Hold, with no Sell or Strong Sell ratings.

S&P Global (SPGI) has a modest dividend yield of 0.91%, but its performance has been lackluster with a 1-year return of -19.73%, while the 5-year return stands at a more favorable 12.86%. Analysts maintain a positive outlook with a consensus rating of Buy and a median 12-month price target of $548.00, suggesting potential upside from its current valuation.

S&P Global (SPGI) has a consensus rating of Buy from 15 analysts, with 33% recommending a Strong Buy and 67% recommending Buy.

S&P Global (SPGI) has an average dividend yield of 5.49% over the past 12 months, indicating a strong dividend performance.

SPGI's current P/E ratio of 28.70x is below historical averages, suggesting potential undervaluation, with an intrinsic value estimated at $452.118 compared to the current price of $425.27.

Boston Scientific (BSX) has faced a challenging year with a significant 1-year return of -31.07%, yet it shows resilience with a strong 5-year return of 80.05%. Analysts are optimistic, maintaining a consensus rating of Buy and setting a median 12-month price target of $110.00, suggesting potential upside from current levels. However, investors should remain cautious due to ongoing investigations into the company’s sales performance.

Boston Scientific (BSX) has a consensus rating of Buy from 19 analysts, with 47% recommending a Strong Buy and 53% recommending Buy.

BSX stock is declining due to investigations by multiple law firms into potential securities fraud related to lower-than-expected sales in its electrophysiology division.

Analysts show strong confidence in BSX, with 35 Buy ratings and an average target price of $103.82, suggesting a potential upside of 50.18% from its current price.

Arista Networks (ANET) has delivered impressive performance with a 1-year return of 56.29% and a remarkable 5-year return of 541.76%. Analysts maintain a positive outlook with a median 12-month price target of $184.50 and a consensus rating of Buy, highlighting the stock's strong position in the hyperscale and cloud sectors. With no analysts advising a sell, ANET appears well-positioned for continued growth.

Arista Networks (ANET) has a consensus rating of Buy from 16 analysts, with 44% recommending a Strong Buy and 50% recommending a Buy.

Arista is favored for hyperscale, cloud, and AI applications, while Cisco is better suited for hybrid and enterprise AI deployments.

Analysts project that ANET could trade between $270.70 and $1,353.50 by 2030.

CoStar Group (CSGP) is recognized as a leader in real estate data platforms, presenting itself as an undervalued growth stock currently trading 36% below its fair value. Despite a challenging performance with a 1-year return of -49.89% and a 5-year return of -50.41%, analysts have a consensus rating of Buy, with a median 12-month price target of $68.00, suggesting potential upside for investors.

CoStar Group (CSGP) has a consensus rating of Buy from 13 analysts, with 31% recommending a Strong Buy and 46% a Buy.

First Majestic Silver has a Strong Buy rating with a 71.05% probability of outperforming the market in the next three months.

Viridian Therapeutics (VRDN) has a consensus rating of Buy from 11 analysts, with 55% recommending a Strong Buy.

Dominion Energy (D) has a consensus rating of Hold from 10 analysts, with 70% suggesting holding the stock.

Equifax (EFX) stands out as a top long-term growth pick, driven by its innovative expansion in U.S. credit bureau services through strategic acquisitions. Despite a challenging year with a 1-year return of -28.94% and a modest 5-year return of -5.68%, analysts maintain a positive outlook, with a median 12-month price target of $235.00. The stock currently offers a dividend yield of just over 1%, appealing to investors seeking opportunities in a company poised for mid-single-digit revenue growth in its U.S. Information Solutions segment.

Equifax (EFX) has a positive outlook due to projected mid-single-digit growth in USIS revenue, driven by favorable pricing changes in the US mortgage market.

EFX's weekly volatility has remained stable at 6% over the past year.

The average price target for Equifax is $236.33, with estimates ranging from $195.00 to $293.00, indicating a potential increase of 30.21% from its last closing price of $181.50.

Analysts are bullish on Equifax, with 66.7% rating it a Buy/Overweight and 33.3% neutral, while none rate it as bearish.